Sébastien Dharancy is an expert in Hepatology at Centre Hospitalier Universitaire de Lille (France). As of June 2026, ScienceLeadR ranks Sébastien Dharancy in the top 1% of experts worldwide for Liver Transplantation and Tissue Transplantation. Sébastien Dharancy has authored 355 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 4 of them ongoing. SLR score: 981 (community average: 125). How the SLR is computed.

LeadR Profile

981 ScienceLeadR Reputation 981
Network Map

Hepatology

Subspecialties: Gastroenterology - Transplantation - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026

Source: PubMed

Centre Hospitalier Universitaire de Lille

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 355

Citations

Citations: 15 114 1st author: 27 Last author: 30 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive management.
PMID 41720193 — liver transplantation, liver, immune checkpoint inhibitors, transplants, transplantation
Am J Transplant20260
Meta-analysis of reference values of cardiorespiratory fitness and impact of interventions in patients with cirrhosis.
PMID 41603324 — liver diseases, exercise, liver transplantation, muscles, physical fitness, cardiorespiratory fitness, transplantation, prognosis
Expert Rev Gastroenterol Hepatol20260
The Impact of Hyperbaric Oxygen Therapy in Liver Donors Before Controlled Circulatory Death on Graft Function Recovery: A Pilot Study.
PMID 41394516 — pilot projects, liver transplantation, pilots, recycling, liver, reperfusion injury, transplants, hyperbaric oxygenation, therapeutics, transplantation
Transpl Int20250
Features and outcomes of 280 patients with idiosyncratic drug-induced liver injury: the REFHEPS prospective study.
PMID 41197933 — registries, pharmaceutical preparations, digestive system diseases, neoplasms, liver, immune checkpoint inhibitors, sex, prospective studies
Clin Gastroenterol Hepatol20250
Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
PMID 41152031 — liver diseases, liver transplantation, liver, therapeutics, transplantation
J Hepatol Top journal20250

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 10
Phase 3 2
Phase 4 2
Phase 2/Phase 3 1

By status:

Completed 9
Recruiting 4
Active not recruiting 1
Unknown 1

By type:

Interventional 9
Observational 6

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 1
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 17

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
LEOPARD Training and Validation Data Collection Study
NCT06675604 — liver transplantation, mortality, cholangitis, liver cirrhosis, patient dropouts, data collection, liver, cholangitis, sclerosing, transplants, artificial intelligence, liver cirrhosis, biliary, transplantation, carcinoma
N/ARecruiting2025
Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation
NCT06535945 — liver transplantation, serum albumin, serum, kidney, liver, serum albumin, human, transplantation, acute kidney injury
Phase 4Recruiting2025
ADDICTOlogical Intervention in LIVEr Transplantation Recipients
NCT06472973 — liver diseases, liver transplantation, comorbidity, hospitalization, liver, alcoholics, risk factors, transplants, therapeutics, outpatients, transplantation, alcohol abstinence, male, men
N/ARecruiting2024
Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)
NCT06354179 — quality of life, liver transplantation, safety, blood, pharmaceutical preparations, adrenal cortex hormones, tacrolimus, liver, transplants, therapeutics, immunosuppression therapy, transplantation, mycophenolic acid
Phase 4Recruiting2025

LeadR Networks

Main global connection map